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Table 1. Risk of side effects from ingestion of omega-3 PUFA [6].
Gastrointestinal upset Clinical bleeding Fishy aftertaste Worsening glycemiaa Rise in LDL-Cb
Up to 1 g/d Very low Very low Low Very low Very low
1 to 3 g/d Moderate Very low Moderate Low Moderate
>3 g/d Moderate Low Likely Moderate Likely
LDL-C, low density lipoprotein–cholesterol.
aUsually only in patients with impaired glucose tolerance and diabetes.
bUsually only in patients with hypertriglyceridemia.
JOURNAL OF HEPATOLOGYAmerican Heart Association recommends at least two ﬁsh meals
per week to healthy people, and a supplemental therapy with 1 g
of omega-3 PUFA per day to those with myocardial infarction [6].
Omega-3 PUFA may treat NAFLD and CVD simultaneously, killing
two birds with one stone [10].
In this review, the average dose of omega-3 PUFA was 4 g/day
(range: 0.8–13.7 g/day), and the authors found no reports of
adverse effects of omega-3 PUFA supplementation in the studies
reviewed. We should be cautious about this conclusion, because
side effects of omega-3 PUFA supplementation do exist (Table 1).
We agree to adopt therapeutic regimen for NAFLD. However,
we sincerely hope that the researchers take the CVD risk and
the side effects of omega-3 PUFA in NAFLD into account when
they determine the optimal dose of omega-3 PUFA. Because
omega-3 PUFA could treat NAFLD and CVD, it is promising to con-
sider that the optimal dose of omega-3 PUFA could be applied for
NAFLD associated risk of CVD. Of course, the hypothesis needs to
be validated by well-designed randomized controlled trials.
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Reply to: ‘‘The optimal dose of omega-3 supplementation for
non-alcoholic fatty liver disease’’To the Editor:
We read with interest the letter by Drs. Li and Chen regarding our
systematic review and meta-analysis of omega-3 supplementa-
tion in non-alcoholic fatty liver disease (NAFLD) [1]. We showed
that, when compared with a control therapy, dietary omega-3
supplementation led to beneﬁcial changes in liver fat in adults.
On the basis of the pooled results of studies, which employed
omega-3 supplementation of 0.83–13.7 g per day, we observed
a statistically signiﬁcant beneﬁt on liver fat, which persisted even
when only randomized controlled trials were examined.
Due to the strong association between NAFLD and cardiovas-
cular disease (CVD), the importance of CVD to mortality in
patients with NAFLD, and the beneﬁt of omega-3 supplementa-
tion in CVD risk reduction, Li and Chen suggest that the optimalJournal of Hepatology 20dose of omega-3 should be higher than 0.83 g per day. We point
out that pooling of data by meta-analysis is a useful tool for
objectively evaluating the consensus of a therapy such as
omega-3 supplementation (vs. a suitable control). However, the
heterogeneity and relative paucity of data entail that these
results should not be used to inform clinical recommendations
on issues such as optimal dosage in NAFLD Using the data from
trials in cardiovascular disease of omega-3 supplementation to
recommend a particular omega-3 dose for NAFLD would be an
inference, not supported by the NAFLD data we have presented.
As stated in our manuscript, more data from randomized con-
trolled trials are required for this. While our meta-analysis
substantiates the efﬁcacy of omega-3 supplementation for mod-
ifying liver fat per se, the choice of dose in an individual with12 vol. 57 j 467–477 469
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The University of Sydney, AustraliaNAFLD will depend on an assessment by the clinician of whether
in fact he/she has cardiac or other co-morbidities.
We found no reports of adverse events for omega-3 supple-
mentation in the relatively limited pool (nine) of studies, which
met the criteria for inclusion in our review. However, we whole-
heartedly agree that these shouldnot be used to reﬂect the consen-
sus of all intervention trials involving omega-3 supplementation.
As Drs. Li and Chen have correctly highlighted, side-effects of
omega-3 supplementation have been reported in previous studies,
which did not have liver fat and serum aminotransferases as inclu-
sion criteria [2].
Our study provides an important ﬁrst step in establishing an
hepatic beneﬁt of omega-3 therapy in adults, but caution should
be taken when interpreting the clinical implications of the meta-
analysis. Our ﬁndings should serve as a stimulus for future
research examining issues such as dose-responsiveness, safety
and patient tolerance with omega-3 therapy.
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Severe cutaneous eruptions on telaprevirTo the Editor:
Since its approval by the Food and Drug Administration in May
2011, telaprevir, a novel serine protease inhibitor, in combination
with peginterferon and ribavirin has been increasingly used as an
effective treatment for hepatitis C virus (HCV) [1]. In phase II and III
clinical trials involving over 3800 patients, a cutaneous eruption,
usually eczematous, occurred in 56% of patients compared to 34%
taking peginterferon and ribavirin alone [2]. Furthermore, 3.7% of
telaprevir-treated patients developed severe cutaneous adverse
events. These events included 11 patients considered to have drug
reactionwith eosinophilia and systemic symptoms (DRESS), but of
these, only one was deﬁnite, two were probable, and the remain-
ders were possible, according to diagnostic criteria proposed by
Kardaun et al. [2,3]. Herein, we report three patients out of 56
patients at risk (5%) taking telaprevir, peginterferon, and ribavirin
at our institution, who developed probable and deﬁnite DRESS.Case 1
470 Journal of Hepatology 201extremities, chest, abdomen, and back (Fig. 1). The morphology
of the rash was consistent with DRESS and involved >50% of his
body surface area (BSA). The skin was pruritic but without ten-
derness, blisters, mucous membrane involvement, facial swelling,
nor lymphadenopathy; however, he had left shoulder pain. On
laboratory data, he was noted to have an absolute eosinophilia
of 805 cells/ll (normal 0–500 cells/ll), thrombocytopenia of
37 K/ll (normal 150–400 K/ll), atypical lymphocytes, and eleva-
tions in alanine and asparate aminotransferases to 45 and 74,
respectively (normal 0–40 IU/L), thus fulﬁlling over ﬁve diagnos-
tic criteria for a deﬁnite case of DRESS [3]. All three antiviral ther-
apies were discontinued. A skin biopsy demonstrated eosinophils
and was consistent with DRESS. He was managed symptomati-
cally with topical class I corticosteroids and systemic antihista-
mines. Unfortunately, 2 months after discontinuation of his
antivirals, his HCV VL has returned to >5 million IU/ml, and he
is being considered for combination therapy with boceprevir,
ribavirin and peginterferon.A 60-year-old man with cirrhosis of the liver in week seven of
treatment with telaprevir, ribavirin, and peginterferon alfa-2A
for chronic HCV was admitted for fever of 39 C, new shoulder
pain, and rash of four-day duration. The patient had previously
failed conventional treatment with peginterferon and ribavirin.
On telaprevir-based therapy, his HCV viral load (VL) was reduced
from >9 million copies IU/ml prior to therapy, to undetectable
after four weeks. Partially blanchable, bright, erythematous pap-
ules coalescing into larger plaques covered most of the patient’sCase 2
A 55-year-old female who previously relapsed after peginterfer-
on and ribavirin therapy had a diffuse, pruritic rash, myalgia,
fever, and chills for one month prior to admission. She had been
taking telaprevir, ribavirin, and peginterferon alfa-2A for chronic
HCV with cirrhosis and had an undetectable VL after 8 weeks.
One week prior to admission, she ﬁnished her 12-week course
of telaprevir and remained on ribavirin and peginterferon. Her2 vol. 57 j 467–477
